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The effects of angiotensin II (Ang II) on vascular smooth muscle cells (VSMC) are modulated by reactive
oxygen species (ROS) and also involve integrin engagement. However, the potential link between
alpha1beta1 integrin signaling with NOX system and their combined contribution to Ang II effects on
VSMC have not been investigated. We aimed to elucidate the moslecular mechanisms underlying the
activation of these two pathways in Ang II effects on VSMC.
Ang II-induced VSMC migration (2-fold increase) and proliferation (2.5-fold increase) is modulated by
alpha1beta1 integrin, being inhibited by obtustatin, a speciﬁc alpha1beta1 integrin blocker. Ang II also
stimulates ROS production in VSMC (140%) that is NOX1 dependent, being completely inhibited in NOX1
silenced cells. The ROS production develops in two peaks, and the second peak is maintained by NOX2
activation. Apocynin and obtustatin inhibit the NOX2-associated second peak, but not the ﬁrst peak of
ROS production, which is related to NOX1 activation. Corroborating the involvement of alpha1beta1
integrin, the pretreatment of VSMC with obtustatin impaired Ang II-induced FAK phosphorylation, AKT
activation, p21 degradation and the increase of ILK expression. Silencing of ILK blocked cell migration,
AKT phosphorylation and the second peak of ROS, but partially inhibits (70%) VSMC proliferation induced
by Ang II.
The data demonstrate a novel role for NOX2 in Ang II effects on VSMC, and suggest alpha1beta1
integrin and ILK as target molecules to the development of more effective therapeutic interventions in
cardiovascular diseases.
© 2015 Elsevier Ireland Ltd. All rights reserved.1. Introduction
The initial step for the development of cardiovascular diseases
involves an inﬂammatory process that leads to vascular injury
associated to endothelial damage, extracellular matrix exposure,
aggregation and adhesion of platelets and leukocytes, and the
activation of vascular smoothmuscle cells (VSMC). VSMC activation
can be ampliﬁed by the release/production of inﬂammatory me-
diators, which in turn induces VSMC migration and proliferation
[1,2], leading to neointimal hyperplasia (related to restenosis) [3,4]ologia Celular e Molecular,
Rio de Janeiro (UERJ), Av. 28
51-030, Brazil.
algo).
rved.and ﬁbrous cap generation (related to atherosclerosis) [5,6].
The increase in angiotensin II (Ang II) levels is an early sign of
cardiovascular disease. Moreover, Ang II levels remain above
normal even after the disease is established [7]. Several studies
have shown that Ang II activates VSMC, promoting cell migration
and proliferation [8e11]. These effects are mediated by integrins
and rely, to a great extent, on NOX activity [11,12].
NOX4 is reported to be responsible for the homeostatic pro-
duction of reactive oxygen species (ROS) [13,14] by VSMC, whereas
Ang II receptor 1 (AT1R) directly activates NOX1, thus increasing
ROS production [9]. On the other hand, the involvement NOX2, the
main inducible isoform of NOX in inﬂammatory processes [15], and
a putative player this scenario, has not yet been fully described in
cardiovascular diseases.
Integrins have a crucial role in VSMC activation. The main
J.A. Moraes et al. / Atherosclerosis 243 (2015) 477e485478integrin present in VSMC is alphavbeta3, which binds to vitronectin
and osteopontin [16,17], two extracellular matrix proteins involved
in different VSMC functions. The blockage of alphavbeta3 integrin
by antibodies or selective peptide ligands (known as disintegrins)
[18] prevents VSMC migration and emerge as a promising thera-
peutic option to impair the development of neointimal hyperplasia
[17e19]. A recent study from our group showed that leukotriene B4,
a known pro-inﬂammatory mediator, activates VSMC through an
inside-out alphav-beta3 activation-dependent mechanism [18].
Another important integrin present in VSMC is alpha1beta1, which
binds to collagen type IV, known to be increased in atheromatous
plaque [20]. Early studies have suggested that alpha1beta1 integrin
could be involved in the effect of Ang II-induced arterial wall hy-
pertrophy [21] and VSMC proliferation [22], and also in the stabi-
lization of the atheromatous plaque [23].
Integrin activation triggers multi-vectorial signaling pathways
that can modulate the cell fate. The activation of Focal Adhesion
Kinase (FAK) and Integrin Linked Kinase (ILK) are, in many cells, the
primary signals required for integrin link with the cytoskeleton and
for signal transduction [24]. FAK is well described as a scaffold for
other signaling accessory proteins and enzymes, including ILK. This
latter enzymeworks as a double-function protein, acting both as an
adaptor molecule of actin cytoskeleton, as well as a kinase. ILK is
able to induce AKT phosphorylation and p21 degradation, two
pathways involved in VSMC migration and proliferation [25,26].
The putative involvement of alpha1beta1 integrin and ILK in
Ang II effects on VSMC has been individually reported [21,27].
However, there are no studies investigating a potential link be-
tween both molecules on Ang-II-mediated VSMC activation,
neither their association with NOX activity and with the redox
sensitive mechanisms that may underlie the activation of integrin
signaling triggered by Ang II.
In the present report, we have investigated the inside-out
signaling mechanisms involved in the activation of alpha1beta1
integrin and its association with the NOX system in VSMC. To this
end, we used a selective alpha1beta1 integrin blocker, namely
obtustatin, a disintegrin isolated from Vipera lebetina obtusa snake
venom [28,29], which helped us to provide hitherto unknown in-
formation on the molecular mechanisms involved in integrin
signaling, NOX activation and Ang II effects on VSMC.
2. Material and methods
2.1. Reagents
All reagents are listed in Supplementary methods. Obtustatin
was puriﬁed from V. lebetina obtusa venom as early described [29].
2.2. Cell culture
Primary VSMC were isolated from the aortic arch from naïve
Wistar male rats using an explant method. The protocol was
approved by the Committee on the Ethics of Animal Experimental
of Universidade do Estado do Rio de Janeiro. (CEUA/003/2013). A7r5
VSMC obtained of rat thoracic aorta were originally from the
American Type Culture Collection (Rockville, MD USA). Cell culture
is better explained in Supplementary methods.
2.3. mRNA silencing
A7r5 VSMC were transfected with siRNA for 24 h and attenua-
tion of ILK, NOX1 or NOX2 expression was veriﬁed by Western
blotting. All process of cell silencing is better described in
Supplementary methods.2.4. Cell migration assay
Chemotaxis assay was accomplished in a modiﬁed Boyden
Chamber after 4 h of migration. This assay is better described in
Supplementary methods.
2.5. Reactive oxygen species production
ROS production was measured using CM-H2DCFDA probe. ROS
assay is better described in Supplementary methods.
2.6. Immunoﬂuorescence microscopy
After 1 h of treatment VSMC were ﬁxed and p47phox, actin and
nuclei were stained. p47phox translocation to cell membrane was
quantiﬁed in Adobe Photoshop Software. This assay is better
described in Supplementary methods.
2.7. Western blotting
Total protein content in the cell extracts was determined by the
BCA method. Samples were submitted to Western blotting assay
(described in Supplementary methods).
2.8. Cell proliferation assay
Cell proliferation was measured by cell cycle analysis by ﬂow
cytometry and by MTT assay after 24 h of treatment. These assays
are better described in Supplementary methods.
2.9. Statistical analysis
Statistical analysis was done using one-way analysis of variance
(ANOVA) followed by Bonferroni post-hoc test and p values < 0.05
were considered signiﬁcant.
3. Results
3.1. Ang II activates vascular smooth muscle cells via alpha1beta1
integrin and NOX2
Previous studies have established a role for alpha1beta1 integrin
as a modulator of VSMC activation and proliferation [8,21,22]. To
assess the chemotactic effect of Ang II on primary VSMC, we used
modiﬁed Boyden chambers. As shown in Fig. 1A, Ang II had a potent
chemotactic activity on VSMC and the treatment of cells with
obtustatin, which selectively blocks alpha1beta1 integrin [28,29],
inhibited migration towards Ang II.
Ang II increased ROS production in primary VSMC reaching a
peak after 1 h and remaining high up to 3 h (Fig. 1B). The pre-
treatment with obtustatin did not change ROS production during
the ﬁrst 30 min of incubation with Ang II, but levels of ROS were
maintained constant until 1 h and decreased to control. Obtustatin
alone was devoid of effect on ROS production. The detailed analysis
of ROS production and the effect of obtustatin have shown that ROS
production induced in smooth muscle cells occurred in two stages,
and that obtustatin inhibited only the second part (0.5e1 h) of ROS
production (see Table 1 in Ref [30]).
To be sure that the source of ROS in smooth muscle cells could
be ascribed to by NOX, cells treated with Ang II and incubated with
DPI, a paninhibitor of NOX, were rendered incapable of ROS pro-
duction upon incubationwith Ang II. On the other hand, apocynin, a
selective inhibitor of p47phox (a NOX2 subunit), inhibited only the
second peak of ROS (0.5e1 h) production in Ang II-stimulated cells,
an effect similar to that of obtustatin (Fig. 1C; see Fig. 1 in Ref [30]).
Fig. 1. Cell migration and ROS production induced by angiotensin II in VSMC and the effects of blocking alpha1beta1 integrin and NOX2. Primary VSMC were obtained from rat
aorta. Panel A: cells were treated with vehicle (Ut) or obtustatin (Obt) 100 nM for 15 min and then placed in modiﬁed Boyden chambers. Chemotaxis towards angiotensin II (Ang II)
100 nM was assessed for 4 h at 37 C in a 5% CO2 atmosphere. Membranes were stained and migrating cells were counted by light microscopy. Results are representative of three at
least ﬁve different experiments. Panel B: Time-course of ROS production induced by Ang II 100 nMwith or without Obt 100 nM and assessed by CM-H2DCFDA ﬂuorescence. Panel C:
Cells were activated with Ang II 100 nM for 1 h in the absence or presence of DPI 10 mM, apocynin 10 mM or Obt 100 nM and the ﬂuorescence assessed as above. The results are
representative of three independent experiments. Data are expressed as mean ± SD. *p < 0.05 compared to untreated control; #p < 0.05 compared to stimulated positive control.
Panel D: Primary VSMC were activated with Ang II 100 nM for 1 h in the absence or presence of apocynin 10 mM or Obt 100 nM and the ﬂuorescence of p47phox present in cell
membrane was quantiﬁed using Photoshop software. The results are representative of three independent experiments. Data are expressed as mean ± SD.
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Fig. 2 in Ref [30]). Interestingly, the simultaneous treatment of
VSMC with apocynin and obtustatin did not induce synergic effects
(Fig.1C), suggesting that both compoundsmay exert their effects by
inhibiting a common pathway, possibly involving NOX2 activation.
The p47phox needs all machinery fromNOX2 complex to induce ROS
production, mainly the membrane subunit GP91phox (also called
NOX2). Once it is well described that VSMC contains NOX2 [31,32]
we investigated the presence of this protein in the VSMC line A7r5.
Our results showed that besides NOX1 and NOX4, A7r5 also has
NOX2 at similar levels compared to polymorphonuclear neutro-
phils (a well-known cell that contains NOX2; see Fig. 3 in Ref [30]).
Because of the similar inhibitory effects of apocynin and
obtustatin on ROS production, we investigated the translocation of
the cytosolic subunit p47phox towards cell membrane, a key event
required for NOX2 complex activation. When p47phox interacts with
the NOX2 membrane subunit, NOX2 becomes a full complex and it
is ready to initiate ROS production [13,15]. Fig. 1D shows that Ang II
induced p47phox translocation to plasma membrane and that
apocynin and obtustatin inhibited this effect, indicating a depen-
dence on p47phox and alpha1beta1 integrin for Ang II-induced NOX2
activation (Fig. 1D). The images showing colocalization of p47phox incell membrane can be observed in Fig. 4 in Ref [30]. Interestingly,
p47phox translocation to VSMC membrane started only 20 min after
Ang II stimulus (see Fig. 5 in Ref [30]), corresponding to the second
peak of ROS production.
3.2. Ang II activates integrin-mediated signaling pathways in
vascular smooth muscle cells via alpha1beta1 integrin
As a key connection between integrin and intracellular signaling
pathways, Focal Adhesion Kinase (FAK) is a pivotal molecule that
modulates cell migration. Integrin engagement promotes FAK
autophosphorylation, and its activation forms focal adhesion con-
tacts allowing cell movement [33]. Obtustatin inhibited Ang II-
induced FAK phosphorylation in VSMC, indicating the involve-
ment of alpha1beta1 integrin (Fig. 2A). When active, phosphory-
lated FAK dissociates from ILK, which is released to exert its kinase
activity [16]. As observed in Fig. 2B, in VSMC stimulated with Ang II,
the dissociation of ILK from FAK started 30 min after stimulation,
concomitantly with the peak of phosphorylation. Along with FAK
dephosphorylation ILK signal was progressively diminished
(Fig. 2B). Furthermore, conﬁrming early reports [27,34], we
observed that Ang II, besides activating ILK, also enhanced ILK
Fig. 2. Angiotensin II activates integrin-mediated signaling pathways in VSMC via alpha1beta1 integrin. Primary VSMC were left untreated (Ut) or were incubated with obtustatin
(Obt) 100 nM for 15 min, at 37 C/5% CO2. After pre-treatment VSMC were treated with angiotensin II (Ang II) 100 nM for 15 min (A), until 60 min (B), for 30 min (D) and for 24 h (C,
E). Panel A: Cells were treated with Ang II for 15 min and whole cell lysates were subjected to Western blotting for Focal Adhesion Kinase (FAK), phospho-FAK (pFAK) and b-actin.
Panel B: Time-course of FAK activation. Whole cell lysates obtained at the indicated times after addition of Ang II were immunoprecipitated for FAK subjected toWestern blotting for
Integrin-Linked Kinase (ILK), FAK and pFAK. Panel C: Protocol identical to Panel A except that cells were harvested 24 h after Ang II addition, immunoblotting for ILK. Panel D:
Protocol identical to Panel A except that cells were harvested 30 min after Ang II addition, immunoblotting for AKT, phospho-AKT (pAKT) and b-actin. Panel E: Protocol identical to
Panel A except that cells were harvested 24 h after Ang II addition, immunoblotting for p21. The results are representative of three independent experiments. Data are expressed as
means ± SD. *p < 0.05 vs. untreated control; #p < 0.05 vs the treated with Ang II.
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inhibited by obtustatin (Fig. 2C), suggesting that Ang II may involve
ILK, downstream apha1beta1 integrin, in VSMC activation. AKT and
p21 are known targets for ILK [24], so we showed that Ang II
induced AKT phosphorylation after 30 min of treatment (Fig. 2D) as
well as p21 degradation after 24 h of treatment (Fig. 2E). These
effects seem to bemodulated by alpha1beta1 integrin, as both were
inhibited by obtustatin (Fig. 2D and E). Similar to what was
observed for obtustatin, treatment of VSMCwith LY294002, a PI3K-
AKT inhibitor, impaired the second peak of ROS production induced
by Ang II (see Fig. 6 in Ref [30]).
3.3. NOX1 and ILK modulate Ang II effects on vascular smooth
muscle cells
Although Valente and colleagues (2012) [9] reported that Ang II
rapidly activates NOX1 via AT1 receptor and that NOX1 is involvedin Ang II effects on cell migration and proliferation, the underlying
mechanisms are poorly known.
Due to the absence of speciﬁc inhibitors to NOX1 and ILK,
smooth muscle cells were silenced to both proteins. For this set of
experiments we used A7r5 rat aorta smooth muscle cell line, which
exhibit similar responses to Ang II when compared to primary
VSMC (data not shown). Cells transfected with the speciﬁc vectors
showed, respectively, 90% inhibition in ILK expression, and 50%
reduction of NOX1 expression (see Fig. 7 in Ref [30]). It was not
possible to completely silence NOX1 expression since it caused cell
death (data not shown). However, even this partial NOX1 silencing
strongly inhibited cell migration and fully inhibited ROS production
induced by Ang II (Fig. 3A and B). ILK silencing also blocked cell
migration to Ang II (Fig. 3A), but only inhibited ROS production
after 30 min of incubation (Fig. 3B). Accordingly, we also observed
that ILK interfered with the second peak of ROS production (see
Table 2 in Ref [30]). Furthermore, NOX1 and ILK silencing inhibited
Fig. 3. NOX1 and integrin linked kinase (ILK) modulate angiotensin II effects on VSMC. A7r5 cells were transfected with siRNA to NOX1, ILK or siRNA scramble for 24 h. All
treatments were performed at 37 C/5% CO2. Panel A: Silenced A7r5 cells were subjected to chemotaxis assay towards angiotensin II (Ang II) 100 nM for 4 h at 37 C. Panel B: Time
course of ROS production assessed using CM-H2DCFDA, up to 3 h after addition of treatments. The results are representative of three independent experiments. Data are expressed
as means ± SD; *p < 0.05 vs. untreated control; #p < 0.05 vs Ang II group. Panel C: A7r5 cells were stimulated with Ang II 100 nM for 1 h. p47phox membrane translocation was
quantiﬁed using Adobe Photoshop software. The results are representative of three independent experiments. Data are expressed as mean ± SD.
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to NOX2 activation (Fig. 3C). The images showing colocalization of
p47phox in cell membrane can be observed in Figure 8 in Ref [30].
3.4. Ang II activates FAK via NOX1, and AKT via NOX1 and ILK
We observed that Ang II activates NOX1 and that this activation
modulates VSMC functions. ROS production induced through NOX1
can activate NOX2 secondarily and this effect relies on alpha1beta1
integrin-ILK cross-talk. However, it was yet unclear who activates
who. Thus, we investigated the molecular signaling pathway trig-
gered by Ang II.
To investigate whether the molecular signaling pathway trig-
gered by Ang II involves a possible crosstalk between alpha1beta1
integrin/ILK pathway and NOX system, we investigated FAK acti-
vation in cells knocked-down for NOX1 and ILK. Fig. 4A shows that,
although NOX1 silencing inhibited FAK phosphorylation, ILK
silencing did not interfere with FAK response to Ang II, indicating
that ILK activation is downstream to FAK activation. In addition,
considering that AKT is a direct target of ILK [24,35], we observed
that both NOX1 and ILK silencing inhibited AKT phosphorylation in
VSMC stimulated with Ang II (Fig. 4B).
3.5. Ang II effects on VSMC proliferation involves NOX1/
alpha1beta1 integrin/ILK
Ang II is a classical inducer of VSMC proliferation, a key effect in
the development of cardiovascular diseases [8,10,36]. Here, weconﬁrmed that obtustatin inhibited G2 phase induced by Ang II
(Fig. 5A) which in turn inhibited partially cell proliferation (Fig. 5B).
Interestingly we observed that apocynin also inhibited partially
Ang II effect on VSMC proliferation (Fig. 5B). In an attempt to
establish the correlation of Ang II-induced cell proliferation effect
with the ﬁndings shown in this report, we silenced A7r5 VSMC for
NOX1, NOX2 or ILK. As previously observed for all effects induced
by Ang II, NOX1 is essential to cell proliferation. On the other hand,
ILK and NOX2 silencing partially inhibited cell proliferation
(Fig. 5C), indicating that other signaling pathways may be playing a
role in this Ang II effect.
4. Discussion
Manyworks have pointed to Ang II as one of the most important
mediators involved in the onset and progression of cardiovascular
diseases such as heart failure and atherosclerosis. Its importance in
cardiovascular diseases is made clear by the fact that one of the
mainstays in the therapy of such diseases is the pharmacological
group of compounds interfering with Ang II production (ACE in-
hibitors), its binding to the AT1 receptor (losartan and derivatives)
and some of its consequences (aldosterone receptor blockers).
In the present report we present novel data on the mechanisms
by which Ang II activates smooth muscle cells. This novel mecha-
nism, most likely to be mediated through AT1 receptor involves a
crosstalk between NOX system and alpha1beta1 integrin/ILK
activation.
In cardiovascular diseases, ROS are shown to modulate different
Fig. 4. Angiotensin II activates focal adhesion kinase (FAK) AKT and integrin linked kinase (ILK) via NOX1 in VSMC. All treatments were performed at 37 C/5% CO2. Panel A: A7r5
VSMC silenced for NOX1 or ILK were treated with angiotensin II (Ang II) 100 nM for 15 min and whole cell lysates were subjected to Western blotting for FAK, phospho-FAK (pFAK)
and b-actin. Panel B: Treatment with Ang II for 30 min and immunoblotting for the detection for AKT, phospho-AKT (pAKT) and b-actin. Results are representative of three in-
dependent experiments. Data are expressed as means ± SD. *p < 0.05 vs. untreated; #p < 0.05 vs treated with Ang II.
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Fig. 5. Angiotensin II proliferative effect on VSMC is dependent upon NOX1, alpha1beta1 integrin and integrin linked kinase. All treatments were performed at 37 C/5% CO2. (A) Cell
cycle was assessed through ﬂow cytometer by PI staining (B, C) and cell proliferationwas evaluated through MTT assay. Panel A: Primary VSMC were incubated with obtustatin (Obt)
100 nM for 15 min and after treated with angiotensin II (Ang II) 100 nM for 24 h. Cells were permeabilized with 0.1% Triton and stained with propidium iodide (PI) for 20 min and
then cell cycle was analyzed in a ﬂow cytometer. Panel B: Primary VSMC were incubated with apocynin 10 mM, obtustatin 100 nM for 15 min and after treated with Ang II 100 nM for
24 h. Panel C: A7r5 cells silenced for NOX1, NOX2 or ILK cells were treated with Ang II 100 nM for 24 h. The results are representative of three independent experiments. Data are
expressed as means ± SD. *p < 0.05 vs. untreated; #p < 0.05 vs the treated with Ang II.
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that migration and proliferation induced by Ang II is dependent on
NOX1, which exerts rapid effects once the cells are activated [9]. The
importance of NOX1was demonstrated by our results showing that
Ang II-induced cell migration, ROS production and cell proliferation
were inhibited in NOX1 silenced cells. Moreover, our data also
reveal that in addition of the activation of NOX1 as an early (30 min
after stimulus) critical step for ROS production, NOX2 became an
important player after 30 min. Apocynin, a selective NOX2 inhibi-
tor, affected only the second peak of ROS production. The pivotal
role for NOX2 in Ang II-stimulated VSMC was conﬁrmed in exper-
iments showing that Ang II indeed induced p47phox membrane
translocation, a key step for NOX2 activation. Furthermore, Ang II
failed to induce p47phox membrane translocation in NOX1-silenced
cells, suggesting that NOX2 activation indeed rely on NOX1 previ-
ous activation. Then, is conceivable to assume that Ang II induces
two peaks of ROS production in VSMC, an initial ROS productioninduced by NOX1 activation followed by a sustained ROS produc-
tion by NOX2.
It is well established that VSMC also express NOX4, which is
important for basal ROS production [13,14] and can also modulate
some Ang II effects [37]. In our experimental model we could not
observe Ang II induction of NOX4 expression (data not shown).
Furthermore, since it was reported that Ang II can induce mito-
chondrial ROS production [38], we also askedwhether this potential
source of ROSwould be involved in our experimental conditions.We
found that the ROSproduced byAng II until 1 h after stimulationwas
not derived from mitochondria, which seems to play a role in ROS
production only at the later times (3 h) (see Fig. 9 in Ref [30]). Thus,
we conclude that NOX1 is the main NOX enzymatic complex
involved in triggering Ang II-induced migration, ROS production
and cell proliferation in vascular smooth muscle cells.
Interestingly, our data also point to a more complex signaling
regulation involving alpha1beta1 integrin engagement, downstream
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to that integrin, inhibited only the second peak of ROS production,
and partially inhibited VSMCmigration and proliferation induced by
Ang II. It is important to remark thatwepreviously observed that Ang
II treatment was able to activate alpha1beta1 integrin, leading to
VSMC adhesion to collagen IV, and obtustatin inhibited this effect
(data not shown).
Previous evidence has shown a pivotal role for alpha1beta1
integrin in the development and progression of atherosclerosis.
Due to its property of selectively binding to collagen, alpha1beta1
integrin contributes to smoothmuscle cell proliferation and arterial
stiffness [21e23]. In this scenario, ILK emerges as an attractive
molecule to be investigated since its activation by integrins can
integrate many signaling pathways associated to different cell re-
sponses of smooth muscle cells [16,24,27,39].
We propose that Ang II induces NOX1 activation, which directly
leads to the engagement of alpha1beta1 integrin that in turn leads
to FAK activation. The increase in FAK phosphorylation is transient
(with a peak in 30 min) and it is related to its dissociation from ILK
that becomes active, and thus induces AKT phosphorylation at
Ser473. The integrin activation in many cell types is well known to
induce, via PI3K-PDK, the phosphorylation of AKT at Thr308, which
is involved in the modulation of cell migration [10,25]. However,
AKT further phosphorylation is a key step to ensure full AKTactivity
[39].We observed that AKT phosphorylation at Ser473 was inhibited
in ILK-silenced cells. Furthermore, the treatment of VSMC with the
PI3K inhibitor LY294002 inhibited only the second peak of ROS
induced by Ang II (see Fig. 6 in Ref [30]). Together, these results
suggest that a full AKT activation by ILK is necessary tomaintain the
endogenous production of ROS, which in turn is known to modu-
late VSMC proliferation [11]. Conﬁrming the importance of ILK
activation in these processes, Ang II-induced cell migration was
inhibited by obtustatin and in ILK-silenced cells. Moreover, simi-
larly to obtustatin or apocynin, the silencing of ILK inhibited only
the second peak of ROS production associated to NOX2 activation,
and reduced cell proliferation. Then, our data reveals a very intri-
cate signaling pathway underlying the activation of alpha1beta1
integrin and ILK to trigger NOX2 activation to maintain the pro-
duction of ROS, and stimulate VSMC proliferation after Ang II
challenge.
The ability of Ang II to induce the transactivation of other types
of receptor was early described. Ang II was shown to promote the
inside-out activation of epidermal growth factor receptor, which
induces the ampliﬁcation of ROS production in VSMC. However, in
contrast with our study, no further details were provided in regard
to NOXs involvement.
In summary, we showed that Ang II-induced ROS production is
NOXs dependent and the initial ROS production induced by NOX1
leads to NOX2 activation, which sustains the effect. We also show
that alpha1beta1 integrin/ILK crosstalk is a link between NOX1 and
NOX2 activation, which in turn is responsible for Ang II-induced
VSMC migration and proliferation (see Fig. 10 in Ref [30]). These
results point to alpha1beta1 integrin as a promising target for
therapeutic treatment in cardiovascular diseases and ILK as a
possible target to be considered in pharmacological interventions.
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